Sparreboom A - Search Results

1

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.

Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD. Cusatis G, et al. Among authors: sparreboom a. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42. doi: 10.1093/jnci/djj469. J Natl Cancer Inst. 2006. PMID: 17148776

2

Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.

Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Viganò L, Locatelli A, de Vos AI, Nooter K, Stoter G, Gianni L. Sparreboom A, et al. Clin Cancer Res. 1998 Aug;4(8):1937-42. Clin Cancer Res. 1998. PMID: 9717822

3

The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies.

de Jonge MJ, Sparreboom A, Verweij J. de Jonge MJ, et al. Among authors: sparreboom a. Cancer Treat Rev. 1998 Jun;24(3):205-20. doi: 10.1016/s0305-7372(98)90050-0. Cancer Treat Rev. 1998. PMID: 9767735 Review. No abstract available.

4

Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva.

de Jonge MJ, Verweij J, Loos WJ, Dallaire BK, Sparreboom A. de Jonge MJ, et al. Among authors: sparreboom a. Clin Pharmacol Ther. 1999 May;65(5):491-9. doi: 10.1016/S0009-9236(99)70068-8. Clin Pharmacol Ther. 1999. PMID: 10340914 Free article. Clinical Trial.

5

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.

Sparreboom A, Planting AS, Jewell RC, van der Burg ME, van der Gaast A, de Bruijn P, Loos WJ, Nooter K, Chandler LH, Paul EM, Wissel PS, Verweij J. Sparreboom A, et al. Anticancer Drugs. 1999 Sep;10(8):719-28. doi: 10.1097/00001813-199909000-00005. Anticancer Drugs. 1999. PMID: 10573204 Clinical Trial.

6

Oral topoisomerase 1 inhibitors in adult patients: present and future.

Gelderblom HA, DE Jonge MJ, Sparreboom A, Verweij J. Gelderblom HA, et al. Among authors: sparreboom a. Invest New Drugs. 1999;17(4):401-15. doi: 10.1023/a:1006394610219. Invest New Drugs. 1999. PMID: 10759406 Review.

7

Topotecan lacks third space sequestration.

Gelderblom H, Loos WJ, Verweij J, de Jonge MJ, Sparreboom A. Gelderblom H, et al. Among authors: sparreboom a. Clin Cancer Res. 2000 Apr;6(4):1288-92. Clin Cancer Res. 2000. PMID: 10778953 Clinical Trial.

8

The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J. van Zuylen L, et al. Among authors: sparreboom a. Clin Cancer Res. 2000 Apr;6(4):1365-71. Clin Cancer Res. 2000. PMID: 10778964 Clinical Trial.

9

Mitomycins.

Verweij J, Sparreboom A, Nooter K. Verweij J, et al. Among authors: sparreboom a. Cancer Chemother Biol Response Modif. 1999;18:46-58. Cancer Chemother Biol Response Modif. 1999. PMID: 10800477 Review. No abstract available.

10

Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.

de Jonge MJ, Loos WJ, Gelderblom H, Planting AS, van der Burg ME, Sparreboom A, Brouwer E, van Beurden V, Mantel MA, Doyle E, Hearn S, Ross G, Verweij J. de Jonge MJ, et al. Among authors: sparreboom a. J Clin Oncol. 2000 May;18(10):2104-15. doi: 10.1200/JCO.2000.18.10.2104. J Clin Oncol. 2000. PMID: 10811676 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

390 results

Search Page

Filters